Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people begin to lose weight on Wegovy within the first four weeks, though the rate varies considerably from person to person. In the STEP 1 clinical trial, participants lost an average of around 15% of their body weight over 68 weeks at the 2.4mg maintenance dose — that works out to roughly one to two pounds a week during the active phase of treatment, with the pace slowing as weight stabilises. The speed depends on your starting weight, how your body responds to semaglutide, and how closely a reduced-calorie diet and regular activity run alongside treatment. Wegovy is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people start Wegovy expecting the most dramatic changes in the first few weeks, and feel anxious when the scales barely move. The reality is almost the opposite. The dose you begin on (0.25mg) is there to let your digestive system adjust, not to drive weight loss. Appetite suppression builds gradually as the dose increases across roughly four months of titration. So early progress is often modest, and that is entirely by design.
What the trial data actually shows is a curve, not a cliff. In the STEP 1 trial published in the New England Journal of Medicine, participants lost weight most rapidly between months two and seven. The rate then slowed, and weight largely plateaued by around 60–68 weeks. Treating the early weeks as a verdict on whether Wegovy is working is one of the most common misunderstandings our prescribers encounter.
If you want a sense of what early milestones typically look like, the detail on what to expect week by week on Wegovy is worth reading before you start.
Once patients reach the 2.4mg maintenance dose (usually around week 17) most experience a more noticeable reduction in appetite, and weight loss tends to accelerate. In the STEP 1 trial, around 70% of participants had lost at least 5% of their body weight by week 28. If you are wondering how fast you should be losing weight on Wegovy, the average total loss over the full 68 weeks was approximately 15%, but there was real variation: some people lost closer to 10%, others over 20%.
A rough practical guide: many people lose roughly 1–2 lbs per week during the most active phase, though this is not a target and individual variation is wide. Factors that influence pace include baseline weight (people with higher starting weights often see faster early loss in absolute terms), metabolic factors, sleep, stress, and how much dietary and activity change runs alongside the injection. The NHS patient information page for semaglutide is a useful companion for understanding what the medicine is doing in your body.
For a broader picture of how the numbers compare across the Wegovy evidence base, and to understand how fast you can lose weight on semaglutide more generally, that page covers the range in more depth.
A plateau is not failure. It is the expected biological response once the body finds a new equilibrium at a lower weight. In the STEP 1 trial, weight largely stabilised by around week 60. At that point, continuing treatment helps maintain the loss rather than deepen it, and discontinuing without sustainable habits in place is associated with weight returning. This is why Wegovy as a treatment is most effective when it is part of a broader plan, not a standalone fix.
If loss has stalled well before expected (say, before week 40 on the maintenance dose) that is worth raising with your prescriber. It may reflect dose tolerability, dietary patterns, or an unrelated factor. NICE guidance recommends reviewing whether to continue if less than 5% weight loss has occurred after six months at the maintenance dose. The right answer depends on your clinical picture, not a number on a scale alone.
Thinking about what Wegovy costs as a private treatment? Our Wegovy cost page explains what a legitimate private prescription includes.
The GI side effects that are most common with semaglutide (nausea, loose stools, indigestion, fatigue) tend to peak at dose increases and settle within a few days to two weeks for most people. They can affect appetite (sometimes reducing it further, sometimes making eating difficult) and energy for activity, which in turn touches the rate of loss.
The good news is that these effects are usually front-loaded. By the time the higher doses are reached, most people have adjusted. Keeping the pen in the same place each week (some people store it in the fridge door so it becomes part of a routine) can help with consistency, which matters for outcomes. If side effects are significant enough to interrupt treatment or stall a dose increase, that conversation belongs with your prescriber. For a fuller picture of what the semaglutide side-effect profile looks like over time, how long it takes for Wegovy to work covers both the appetite changes and the adjustment phase in detail.
Questions about what to expect at each stage of treatment are ones our clinical team field regularly. If Wegovy sounds like something worth exploring, check your eligibility with our prescribers, the consultation is free and reviewed the same day by a real clinician.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.